Quanterix Corporation (QTRX)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 15 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Quanterix’s second fiscal quarter of 2026 results missed expectations on both the top and bottom line, with the company reporting on August 10, 2026 that EPS of -$1.04 trailed the -$0.41 estimate by -$0.63 while revenue of $32.9 million trailed the $37.5 million estimate (-12.2%). Revenue rose ~35% year over year to about $32.9 million from $24.5 million a year ago, spanning its instruments, consumables, and lab services lines, but losses widened as net income fell 63% year over year to roughly -$48.9 million versus -$30.0 million a year ago and EPS declined 35.1% from -$0.77. Profitability remained deeply negative, with gross profit of about $12.7 million translating to a gross margin of roughly 39%, while operating income was about -$49.4 million and operating margin stood at about -150%. Despite the net loss, Quanterix generated operating cash flow of roughly $2.6 million and repurchased about $0.3 million of stock during the quarter. For the next period, consensus calls for EPS of -$0.43 on revenue of $34.7 million.
Next report — what to expect
Quanterix Corporation (QTRX) reports earnings on November 9, 2026. Wall Street expects EPS of -$0.429 on revenue of $34.7 million. For trailing context, revenue grew +34.6% year over year last quarter. Quanterix has beaten EPS in 2 of 8 most recent quarters, so attention may center on delivery versus consensus.
About Quanterix Corporation
Quanterix Corporation develops and sells digital immunoassay tools and related services for research and diagnostic work in healthcare, with its shares listed on the NASDAQ under QTRX. Its portfolio spans instruments, consumables, and lab services, and it generated $138.7 million of revenue in FY2025.
Today's Snapshot
QTRX closed 0.7% higher at 2.86, outperforming a weaker sector.
Trading Volume
Below 10d avg (459.0K)
332.6K
vs S&P 500 Today
Outperforming Market
+1.22%
Updated: October 23, 2026 at 20:21 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$2.94 - $4.10Sell
- RSI (14)42.74Neutral
- Stochastic %K (14, 3, 3)11.54Buy
- MACD Level (12, 26)-0.09Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.